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A B S T R A C T
Background: 22q11.2 deletion syndrome (22q11DS) is a genetic disorder associated with neurodevelopmental,
anxiety and mood disorders, as well as an increased risk for developing psychosis. Cortisol levels and stress
reactivity reflect hypothalamic-pituitary-adrenal (HPA)-axis activity, and are believed to be altered in in-
dividuals that often experience daily-life stress, depression, and psychotic symptoms. However, it is unknown
whether individuals with 22q11DS display an altered stress reactivity.
Methods: We included 27 adults with 22q11DS (mean age: 34.1 years, 67% female) and 24 age and sex-matched
healthy controls (HC; mean age: 39.9 years, 71% female) into an experience sampling study. Throughout 6
consecutive days, we measured participants’ subjective stress related to current activity and at the same time
collected salivary cortisol samples. Multilevel regression models were used to analyze cortisol reactivity to ac-
tivity-related stress.
Results: Diurnal cortisol levels were significantly lower in the 22q11DS group compared to HCs (B=-1.03,
p < 0.001). 22q11DS adults displayed significantly attenuated cortisol reactivity to activity-related stress
compared to HCs (B=−0.04, p= 0.026). Post-hoc exploratory analysis revealed that these results were in-
dependent from 22q11DS psychiatric diagnosis or medication use.
Conclusion: These results indicate that adults with 22q11DS have lower cortisol levels and attenuated cortisol
response to daily stress, possibly resulting from an increased sensitization of the HPA-axis. This suggests that
alterations in HPA-axis functioning, previously reported in several psychiatric disorders including post-traumatic
stress disorder (PTSD), psychotic disorder, and mood disorder, also appear to be present in adults with 22q11DS.
1. Introduction
The 22q11.2 deletion syndrome (22q11DS) is a genetic disorder
caused by a microdeletion on the long arm of the 22nd chromosome,
resulting in hemizygosity of approximately 50 genes (Murphy et al.,
1999; Bassett et al., 2005; Schneider et al., 2014; McDonald-McGinn
et al., 2015; Gur et al., 2017). Occurring in 1 out of 2000–4000 live
births, it is one of the most common recurrent copy number variant
disorders. The syndrome is associated with impairments in socio-emo-
tional functioning (e.g., deficits in socialization, comprehension and
social judgment) and somatic health (e.g., cardiac abnormalities, facial
dysmorphology, immunodeficiencies, and early-onset Parkinson’s dis-
ease)(Bassett et al., 2005; Schneider et al., 2014; Fung et al., 2015). In
addition, patients generally have intellectual impairments, varying
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from borderline IQ to moderate-severe intellectual disability (average
IQ of 70–85)(Bassett et al., 2005; Schneider et al., 2014), and a high
risk of developing mental disorders, including mood disorders
(23–53%), attention deficit hyperactivity disorder (36%), autism spec-
trum disorder (25–50%), and psychosis (20–40%)(Vorstman et al.,
2006; Green et al., 2009; Schneider et al., 2014).
It has been suggested that the wide variety of physical and mental
health problems is partially related to the high rates of chronic stress in
individuals with 22q11DS (Beaton and Simon, 2011). The clinical
phenotype of 22q11DS includes greater susceptibility to stress and
anxiety, and poorer coping skills (Swillen et al., 1999; Beaton and
Simon, 2011). Moreover, since children with 22q11DS often have to
face medical (e.g., frequent hospitalizations and surgery (Mahle et al.,
2003; Carotti et al., 2008)), cognitive (e.g., delayed cognitive devel-
opment)(Gur et al., 2014; Swillen and McDonald-McGinn, 2015), and
social challenges (e.g., bullying) (Swillen et al., 1999)) early in life, it is
very likely that they may experience chronic stress, especially in in-
fancy (Beaton and Simon, 2011; Vo et al., 2018). However, no study to
date has investigated whether individuals with 22q11DS and healthy
controls (HCs) differ in their experience of- and exposure to childhood
adversity and chronic stress.
Early-life stress can have several persisting effects, which include
epigenetic alterations (Jawahar et al., 2015), impaired brain develop-
ment (Andersen et al., 2008; De Bellis and Zisk, 2014), and an increased
risk of developing psychiatric disorders (Green et al., 2010; Kessler
et al., 2010; Varese et al., 2012; Jawahar et al., 2015). Meanwhile,
stressful events during adulthood are thought to increase risk for psy-
chiatric disorders in vulnerable individuals, and may precede the onset
of a psychotic episode (Lukoff et al., 1984; Corcoran et al., 2003).
The ability to adaptively respond to stressful events is modulated by
hypothalamic-pituitary-adrenocortical (HPA) axis activity: the stress-
regulating system secreting cortisol in response to (potentially) stressful
events (Nicolson, 2008). It is suggested that long term exposure to stress
and excessive activation of the HPA-axis can alter HPA-axis functioning
and cause sensitization of the stress response (McEwen, 2004). Cortisol
follows a diurnal curve with a stark rise shortly after awakening, fol-
lowed by a gradual decrease over the day. Flattened curves are asso-
ciated with poorer physical and mental health (Adam et al., 2017),
possibly due to HPA-axis dysfunction. Impaired cortisol reactivity in
general is associated with psychiatric disorders (Holtzman et al., 2013;
Zorn et al., 2017) also often reported in 22q11DS (Schneider et al.,
2014; Fung et al., 2015) including depression (Kendler et al., 1999),
anxiety (Moreno-Peral et al., 2014) and psychosis (Holtzman et al.,
2013).
Given the abovementioned relevance of stress reactivity for mental
and somatic health, it is rather surprising that little attention has been
paid to the HPA axis function in 22q11DS adults. To our knowledge,
only two studies (both in children) investigated cortisol and stress re-
activity in 22q11DS individuals (Jacobson et al., 2016; Sanders et al.,
2017). Jacobson and colleagues (Jacobson et al., 2016) found increased
end-of-the-morning cortisol levels (collected around 11:00 h) in a
sample of 11 children with 22q11DS compared to HC. Another study
investigating cortisol reactivity to a stressful working memory task, did
not find significant differences in cortisol reactivity and recovery in
relation to the task in 20 children with 22q11DS (Sanders et al., 2017).
However, compared to HCs, an overall increase in afternoon salivary
cortisol levels in 22q11DS relative to HCs were detected, potentially
indicating abnormal HPA-axis functioning in this group. Interestingly
recent work in 22q11DS also confirms the central role of stress and
coping in the pathway to psychosis in 22q11DS (Armando et al., 2018).
Studies using the experience sampling method (ESM) (Myin-
Germeys et al., 2018), a structured diary technique, showed increased
stress sensitivity (here, the emotional responses (positive and negative
affect) to daily stress events) in (non-22q11DS) individuals with psy-
chotic disorder and first-degree relatives of these patients (Myin-
Germeys et al., 2009; Reininghaus et al., 2016). ESM can be used for
assessment of situational variables, outside of an artificial clinical or
laboratory setting (Bolger et al., 2003; Myin-Germeys and van Os,
2007), and has previously been used to investigate cortisol reactivity to
stressful events in clinical and non-clinical populations (Peeters et al.,
2003; Jacobs et al., 2007; Collip et al., 2011a,b). ESM is exceptionally
suitable for investigating cortisol fluctuations and responses to en-
vironmental challenges (i.e., stressors) (Peeters et al., 2003; Jacobs
et al., 2007; Collip et al., 2011a,b). In first-degree relatives of patients
with psychotic disorders, higher overall cortisol levels and increased
cortisol response to daily life stressors have been found (Collip et al.,
2011a,b). Another recent ESM study reported an altered cortisol re-
sponse to stressful activities in patients with psychotic disorders com-
pared to HCs (Vaessen et al., 2018). ESM is therefore a suitable method
to investigate stress reactivity in individuals with 22q11DS, and has
never been used in this population before.
To summarize, individuals with 22q11DS show increased suscept-
ibility to stress and anxiety, and may be more exposed to and experi-
encing chronic (childhood) stress compared to HCs. Haploinsufficiency
of around 50 genes makes 22q11DS a unique model to investigate the
neurobiology underlying stress reactivity in general and in 22q11DS
specifically. The current study therefore aims to examine, for the first
time, overall cortisol levels, diurnal slope, and cortisol reactivity to
daily life stressors using ESM in adults with 22q11DS. Based on pre-
vious findings (Jacobson et al., 2016; Sanders et al., 2017), we hy-
pothesize that in their everyday lives, individuals with 22q11DS, will
show 1) higher overall cortisol levels, 2) a flatter diurnal slope, and 3)
an blunted cortisol response to activity-related stress, when compared
to the comparison subjects (HCs).
2. Method
2.1. Sample
Written informed consent was obtained from all participants who
entered the study. Participants were treated in accordance with the
Declaration of Helsinki (World Medical Association, 2001). This study
was approved by the Medical Ethical Committee of the University of
Maastricht (NL). After participation the individuals received a coupon
with a total value of 75 euro’s for participating in the study. A total of
55 subjects (n=31 22q11DS) were recruited for the current study. The
Dutch (NL) and Flemish (B) individuals with 22q11DS were recruited
through the Dutch 22q11DS family network, the National Adult
22q11DS Outpatient Clinic at Maastricht University Medical Centre
(NL), the National Children 22q11DS Outpatient Clinic at University
Medical Centre Utrecht (NL), and The Center for Human Genetics of the
University Hospital Leuven (B). In addition, individuals with 22q11DS
who participated in previous studies were approached if they had
agreed to be re-contacted. The 22q11DS sample was compared to a
sample of 24 HCs partially overlapping with a previous study (Kasanova
et al., 2017). Recruitment and inclusion criteria for the HC subjects are
the same as described previously (Kasanova et al., 2017).
The general inclusion criteria were: 1) age between 18–60 years, 2)
sufficient command of the Dutch language, and 3) mental competence
to give informed consent (for the 22q11DS group this was confirmed by
an experienced psychiatrist during an interview before inclusion in the
study). Additionally, for 22q11DS subjects, there had to be a confirmed
deletion at chromosome 22q11.2 (determined by fluorescence in situ
hybridization, multiplex ligation-dependent probe amplification, or
micro-array analysis). General exclusion criteria were 1) current severe
endocrine, cardiovascular, or neurological disease, 2) current alcohol
and/or drugs cannabis dependence (confirmed by the substance abuse
module of the Composite International Diagnostic Interview (CIDI))
(Robins et al., 1988). Additional exclusion criteria for the HC group in
the study were 3) having a lifetime history of Axis I or II disorders as
determined by the Mini-International Neuropsychiatric Interview
(M.I.N.I.)(Sheehan et al., 1998) and 4) current use of neuroleptics,
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steroids, or thyroid medication.
2.2. General procedure
The current study was carried out in two sessions. During the first
session participants completed behavioral questionnaires and they were
briefed about the cortisol sampling and ESM procedure, and received
instructions on how to use the PsyMate™ (www.psymate.eu) (Myin-
Germeys et al., 2011), the electronic device used to collect self-assess-
ments. In between the first and the second sessions ESM assessments
were collected, with at least two telephone calls from the researchers to
verify study compliance. In the second meeting the PsyMate™ and
cortisol samples were recollected, the independent ESM period was
debriefed and the final behavioral assessments were finished.
2.3. Questionnaires / behavioral assessments
During the first session, demographics and medication use were
ascertained. Full scale intelligence quotient (IQ) was assessed for
22q11DS subjects using the shortened version of the Dutch Wechsler
Adult Intelligence Scale (WAIS-III-NL) (Canavan et al., 1986; Wechsler,
1997) consisting of four subtests: arithmetic and information (verbal
IQ) digit-symbol-coding and block patterns (performance IQ) (Brooks
and Weaver, 2005); the Dutch Adult Reading Test (DART) (Schmand
et al., 1991) was used to test IQ in the HC group. The 18-item Brief
Psychiatric Rating Scale (BPRS) was used to rate general psycho-
pathology (Overall and Gorham, 1962). Within the 22q11DS group, the
Mini International Neuropsychiatric Interview (M.I.N.I.) was performed
to confirm psychiatric diagnosis (Sheehan et al., 1998). All participants
completed the Dutch version of the Childhood Trauma Questionnaire
25-item short form (CTQ) (Bernstein et al., 2003). The questions are
rated on a 5-point Likert scale and a general measure of childhood
trauma was generated by calculating the sum of the separate domains,
including Physical abuse, Emotional abuse, Sexual abuse, Physical ne-
glect, and Emotional neglect.
2.4. ESM technique and daily stress measure
ESM is a structured diary method developed to assess participants in
their daily life in a natural setting (Delespaul, 1995; Myin-Germeys
et al., 2009, 2018). Using the PsyMate™, participants were signaled
with a beep at 10 semi-random times per day on 6 consecutive days
between 7:30 h and 22:30 h. After a beep, participants were instructed
to fill out a short questionnaire on the PsyMate™ assessing, among
others, their current mood, activity, and context, which were scored on
a 7-point Likert scale. The use of the device was explained to the par-
ticipants in the first briefing session and a test run of the questionnaire
was done during which each possible item was explained to the parti-
cipant and a parent, partner, or supervisor. Participants were excluded
if they failed to provide valid responses to at least one third of the beeps
and incomplete momentary evaluations were excluded (Myin-Germeys
et al., 2001, 2009; Reininghaus et al., 2016). Level of momentary stress
was based on the score of two items, rating the appraised stressfulness
of the current activity: “I like doing this activity” (reverse coded) and
“This activity is difficult for me”. These questions were rated on a 7-
point Likert scale ranging from 1 to 7 (1= not at all, 7= very much).
There was a moderate positive correlation between the two items
(r= 0.4). The mean of these two items was taken to compute the ac-
tivity-related stress value, with higher scores representing higher levels
of activity-related stress. To control for possible confounders, we as-
sessed recent food/drink intake and nicotine and caffeine use since the
previous beep using yes/no response options.
2.5. (Salivary) cortisol
Saliva samples were collected with every PsyMate™ beep. After each
beep, participants collected a saliva sample using a cotton swab
(Salivette, Sarstedt, the Netherlands). They replaced the swab in the
tube and recorded the collection time, before storage in their home
freezers. During the second meeting the researcher collected the sam-
ples and stored the tubes at −20 °C until analysis at Dresden University
of Technology. Salivary cortisol was analyzed from the saliva samples
in duplicate using radio-immunoassays (Dressendörfer et al., 1992).
Tracer solution Cortisol 3-CMO coupled with 2-[125I]-histamine and
antibodies for Cortisol 3-CMO-BSA was used (Sulon et al., 1978). Cor-
tisol values above 44 nmol/L were removed from the analyses because
they are considered physiologically abnormal (Peeters et al., 2003;
Jacobs et al., 2007; Nicolson, 2008; Collip et al., 2011a,b). Cortisol
values were log-transformed to reduce skewness of distribution, gen-
erating a new additional variable lncort (Collip et al., 2011a,b; Vaessen
et al., 2018), which was approximately normally distributed.
2.6. Statistical analysis
Statistical analyses were conducted in STATA version 13.1
(StataCorp, College Station, TX, USA; 2013). For all analyses, the level
of statistical significance was set to α=0.05. Group differences in
demographic characteristics, mean scores of all combined (ESM) stress
measures, and exposure to childhood trauma were investigated using
chi-square tests and analyses of variance (ANOVA). All further analyses
were carried out using multilevel regression models, which take into
account the hierarchical character of ESM data: momentary observa-
tions (level 1) are nested within days (level 2) which are nested within
subjects (level 3) (Snijders, 1999). Hence, random effects (intercepts)
were added at both the person and day level. We use B to denote the
(unstandardized) regression coefficient of a particular predictor in such
a multilevel model. To test for group differences in mean cortisol levels
over all assessments, a multilevel model was fitted using lncort as the
dependent variable and group as the independent variable (Model 1). In
this model, the diurnal slope of cortisol was estimated using the vari-
able “centered beep time” (the variable time centered around 15:00 h)
and the square of this variable - “centered beep time2” as predictors.
Centered beep time2 did not have a significantly better fit compared to
“centered beep time”, therefore the model with centered beep time was
used, with random slopes for this variable added at person and day
level. To further investigate possible differences in diurnal slopes be-
tween the groups, the group x time interaction term was added to the
model (Model 2). Finally, to investigate if groups differed in cortisol
reactivity to activity-related stressors, activity stress and the group x
activity stress interaction were added as predictors to the model (Model
3) with random slopes for activity stress at the person and day level. In
case of a significant interaction effect, the Lincom command was used
for comparisons. All models control for age, sex, medication use, oral
contraceptive use, recent food and/or drink intake and recent smoking
and/or caffeine use. The models also allowed for autocorrelation be-
tween residuals within a day (using an AR1 autocorrelation structure),
to account for potential autoregressive effects.
3. Results
3.1. Sample (ESM) characteristics
The 55 participants included (n=31 22q11DS and n=24 HCs)
completed 2292 ESM reports and collected 1968 saliva samples. Four
22q11DS participants (with a combined number of 45 valid ESM re-
ports) had to be excluded because they did not provide enough ESM
assessments (less than one -third of the total number of beeps
(Delespaul, 1995; Myin-Germeys et al., 2011), and 7 cortisol samples of
HC participants had to be excluded because they were above the pre-
determined cut-off (mean cortisol> 44 nmol/l). This resulted in a da-
taset of 1916 valid ESM reports and cortisol samples from 51 subjects,
27 22q11DS patients (n=937) and 24 HCs (n=979) (combined 58%
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compliance). Demographics of included participants are shown in
Table 1. Groups did not differ on most demographic characteristics, but
there were significant group differences in level of education, source of
income, mean BPRS score, medication use, and compliance (Table 1).
As expected, given that impaired cognitive function is a core
characteristic of individuals with 22q11DS (Jonas et al., 2014;
Schneider et al., 2014; Yi et al., 2016), IQ was significantly lower in
22q11DS individuals compared to HCs (F(1,49)= 107.73, p < 0.001,
Table 1). CTQ scores did not differ between the 22q11DS and HC
groups.
Table 1
Demographic characteristics and descriptives.
Controls (n= 24) 22q11DS (n=27) Test statistic P value
Sex (n male/n female) 7/17 9/18 X2(1)=0.10 0.75
Age in years, mean (SD) 39.91 (± 13.41) 34.11 (±9.81) F= 2.16 0.15
IQ, mean (SD) 106.09 (±8.36) 78.29 (±10.43) F= 107.73 < 0.001**
Level of education, n (%) X2(2)= 24.22 < 0.001**
Secondary school or less1 1 (4.17%) 14 (51.85%)
Further education 8 (33.33%) 12 (44.44%)
Higher education 15 (62.50%) 1 (3.70%)
Marital status, n (%) X2(1)=1.2 0.28
Married or living together 8 (33.33%) 13 (48.15%)
Never married / single / divorced 16 (66.67%) 14 (51.85%)
Living situation, n (%) X2(3)=3.4 0.33
Alone 6 (25.00%) 4 (14.81%)
With parents / relatives 11 (45.83%) 13 (48.15%)
With partner/family/children/alone with children 7 (29.17%) 7 (25.93%)
Special housing (psychiatric/non-psychiatric institute) 0 (0%) 3 (11.11%)
Source of income, n (%) X2(2)=6.7 0.03*
Salary (work) / student fee 18 (75.00%) 11 (40.74%)
Income from social workplace 0 (0%) 2 (7.41%)
Income from benefit or maintenance2 6 (25.00%) 14 (51.85%)
Work situation, n (%) X2(1)=3.8 0.05
Working / significant housework / studying 18 (75.00%) 13 (48.15%)
Disabled or unemployed 6 (25.00%) 14 (51.85%)
Childhood Trauma Questionnaire (CTQ), mean (SD) (HC n=24, 22q n=26) 34.08 (± 7.62) 33.73 (±8.99) F=0.02 0.88
ESM, mean (SD) (HC n=979, 22q n= 937)
Mean Momentary Cortisol in nmol/l 9.97 (3.08) 3.62 (1.34) F= 94.18 <0.001*
Number of beeps filled out per participant 46.79 (± 7.92) 41.62 (±8.73) F=4.84 0.03*
Momentary activity stress 2.68 (± 0.69) 2.60 (± 1.03) F=0.11 0.74
Momentary caffeine use 0.29 (± 0.21) 0.23 (± 0.20) F=1.17 0.29
Momentary nicotine use 0.09 (± 0.24) 0.09 (± 0.26) F= 0.01 0.93
BPRS total, mean (SD) 18.46 (± 4.30) 22.93 (±5.30) F=10.75 0.002**
Diagnosis (M.I.N.I.), n (%)
Psychotic disorder 0 (0%) 1 (3.7%)
Mood (and Anxiety) disorder 0 (0%) 4 (14.8%)
Only Anxiety disorder 0 (0%) 3 (11.11%)
None 24 (100%) 19 (70.4%)
Oral contraceptive, n (%) 0 (0%) 2 (7.41%) X2(1)=1.85 0.17
Medication3, n (%) 0 (0%) 14 (51.85%)3 X2(1)= 14.67 < 0.001**
1 = Elementary school and high school (Dutch: VMBO, LBO, HAVO or VWO), 2 = Income from benefit or maintenance due to sickness, or unemployment 3 =
Antipsychotics (Risperdal, Zyprexal), Psychoactive (Amitriptyline, Concerta, Paroxetin (n= 2), Priadel, Sertraline, Sipralexa, Strattera, Oxazepamam), Other
medication (Betamethason, Flixonase, Omeprazol).
* p < 0.05.
** p < 0.001.
Table 2
Results from multilevel linear regression analyses of the effects of cortisol reactivity between groups (Model 1), in the interaction of group and time (Model 2), and in
the interaction of group and activity related stress (Model 3).
ln Cortisol Model 1 – Group Model 2 – Time Model 3 – Activity Stress
B S.E. 95% C.I. p B S.E. 95% C.I. p B S.E. 95% C.I. p
Group (HC vs 22q11DS) −1.036 0.109 −1.24 < -> <0.001** −1.032 0.110 −1.24 < -> <0.001** −0.920 0.120 −1.15 < -> <0.001**
−0.82 −0.82 −0.69
Time −0.134 0.006 −0.15 < -> <0.001** −0.137 0.009 −0.15 < ->
-0.12
< 0.001** −0.134 0.006 −0.15 < ->
-0.12
< 0.001**
−0.12
Group x Time x x x 0.006 0.012 −0.02 < -> 0.631 X X x
−0.03
Activity related Stress x x x x x x 0.026 0.013 −0.00 < -> 0.051
−0.05
Group x Activity
related Stress
x x x x x x −0.044 0.020 −0.08 < -> 0.026*
−0.01
**p < 0.001 *p < 0.05 SE= standard error CI= confidence interval HC=healthy controls 22q11DS=22q11.2 deletion syndrome. The dependent variable is log
transformed cortisol (ln Cortisol). The models control for age, sex, medication use, oral contraceptive use, recent food and/or drink intake, and recent smoking and/
or caffeine use (recent= between the interval of two Experience Sampling Method reports, roughly within 90min). The models correct for autocorrelation between
residuals.
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3.2. Cortisol levels and diurnal slope
Mean cortisol levels of all the combined samples were significantly
lower in 22q11DS participants compared to HC (F(1,49)= 94.18,
p < 0.001 Table 1, Fig. 1a). Moreover, multilevel linear regression
analyses revealed that 22q11DS participants had significantly lower
cortisol levels across all ESM sampling moments compared to HCs (B=-
1.03, p < 0.001; Figure 1 & Table 2). There was a significant effect of
time on mean cortisol, showing a significant cortisol decline during the
day, with higher cortisol levels in the morning compared to the evening
(B=−0.13, p < 0.001, Fig. 1 & Table 2). There was no significant
interaction between time and group, suggesting a comparable steepness
of the diurnal decline in cortisol throughout the day between groups
(B=0.01, p=0.63, Fig. 1 & Table 2).
3.3. Cortisol reactivity to daily stressors
There was no significant difference in mean activity-stress between
the groups (Table 1). Multilevel linear regression analyses revealed that
cortisol reactivity to activity-related stress differed significantly
Fig. 1. (a) Mean Cortisol differences including standard
error bars, between healthy controls (HC) (n=24) and the
22q11.2 deletion syndrome (22q11DS) group (n= 27).
**=p < 0.001.(b) Mean Cortisol differences between
healthy controls (HC; n= 24) and the 22q11.2 deletion
syndrome (22q11DS) group (n=27). Modelled change
(based on regression coefficient) in untransformed cortisol
values (nmol/l) over time of the day (in hours). Both
groups have a significant reduction in mean cortisol over
the day (significant main effect of time of the day:
B=−0.14, SE= 0.009, p < 0.001; not significant inter-
action effect of group x time: B= 0.006, SE= 0.012,
p=0.63). 22q11DS have a significant lower cortisol
diurnal slope compared to HC (see Table 2 for statistics).
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between the 22q11DS and HC group (B=-0.044 p= 0.026, Fig. 2 &
Table 2). Whereas in the HC group higher activity related stress seems
to be associated with increased cortisol levels, this cortisol response
seems to be blunted in the 22q11DS group (Fig. 2). Activity-related
stress was trend significantly associated with cortisol reactivity within
the HC group (B= 0.03, SE=0.01, 95% CI -0.00 to 0.05, p= 0.051).
Activity-related stress was not significantly associated with cortisol
reactivity within the 22q11DS group (B=-0.02, SE=0.01, 95% CI
-0.05 to 0.01, p= 0.22). The conclusions did not significantly change
after the inclusion of levels of education and income as a covariate.
3.4. Post-hoc analyses
To further explore the differences between individuals with
22q11DS and HCs, we tested several post-hoc hypotheses to explain the
results described above.
First, we tested the hypothesis that the alterations found in 22q11DS
individuals are associated with higher levels of symptoms indicative of
psychopathology (BPRS) or cognitive disabilities (IQ). We included
BPRS total scores and IQ scores as predictors in the multilevel regres-
sion models. These analyses suggested that neither were significantly
related to cortisol and inclusion of these variables did not alter the main
conclusions and majority of the previous findings. Only a minor change
of significance emerged in the analyses controlling for BPRS, marking
activity stress significantly associated with cortisol in the HC group
(B= 0.03 SD=0.013 95% CI 0.00 – 0.05 p=0.044), where it was
previously only trend significant (Table 2).
Second, we added CTQ as covariate to the models to test the hy-
pothesis that the between-group differences we observed resulted from
chronic alterations due to exposure to (childhood) traumatic events.
CTQ score was not associated with our stress measures (cortisol and
activity-related stress), and the initial findings remained the same.
Finally, we investigated whether the results could be explained by
the effect of medication or M.I.N.I. diagnosis present in the 22q11DS
group. To this end, we repeated our main analysis comparing the
22q11DS group with the HC group with exclusion of participants who
were using medication (22q11DS n=14) and additional analysis ex-
cluding the participants with a M.I.N.I. diagnosis (22q11DS n=8), but
the conclusions remained unchanged.
4. Discussion
Here we report results from the first study to investigate cortisol
levels and cortisol stress reactivity using the ESM method in adults with
22q11DS, a genetically defined population at increased risk for devel-
oping psychiatric disorders. Our main findings suggest that individuals
with 22q11DS show overall lower mean cortisol levels and blunted
cortisol reactivity to activity-related stress compared to HCs. This sug-
gests that alterations in HPA-axis functioning, previously reported in
several psychiatric disorders including post-traumatic stress disorder
(PTSD), psychotic disorder, and mood disorder, thus also appear to be
present in adults with 22q11DS.
4.1. Overall cortisol & diurnal slope
We found lower mean cortisol levels in 22q11DS, in line with
findings in non-clinical populations including people with tempera-
mental shyness and social anxiety (Beaton et al., 2006, 2013) and
findings in patient groups suffering from long term exposure to stress
(Fries et al., 2005), such as PTSD (Yehuda et al., 1996), atypical de-
pression (Gold and Chrousos, 2002; Van Hoof et al., 2003), chronic
fatigue syndrome (Van Hoof et al., 2003; Roberts et al., 2004), and
burn-out (Pruessner et al., 1999). Our cortisol findings in adults with
22q11DS are in contrast to findings in children with 22q11DS, where
elevated cortisol levels were previously found (Jacobson et al., 2016;
Sanders et al., 2017). This may be explained by chronic overactivation
of the HPA-axis (i.e., allostatic load), suggested to lead to a stronger, or
overly sensitive, negative feedback response by cortisol, eventually
resulting in lower cortisol levels, as suggested in PTSD (Yehuda et al.,
1996; Yehuda, 2002; Daskalakis et al., 2013). Both groups were found
to have no difference in CTQ scores, however, which was also not as-
sociated with cortisol in our analyses, thus challenging this explanation.
However, sensitization of the stress system could occur in the absence
of major traumatic events, for instance in response to the lifelong day-
to-day stressful challenges associated with the syndrome (Swillen et al.,
1999; Beaton and Simon, 2011). Minor daily life challenges (or un-
expected events) might additionally be experienced more stressful
(traumatic), potentially associated to the high levels of chronic stress
and anxiety in (children with) 22q11DS (Swillen et al., 1999; Beaton
and Simon, 2011; Phillips et al., 2017; Vo et al., 2018). Future studies
should take these topics into account when investigating cortisol in
22q11DS before any definite conclusions on the role of chronic stress
can be drawn.
The steepness of the diurnal decline in cortisol throughout the day
did not differ between the groups, and although in contrast with our
initial hypothesis, this result is in line with previous studies comparing
HCs with relatives of psychotic patients (Collip et al., 2011a,b) and
individuals with schizophrenia (Jansen et al., 2000). This indicates that
the diurnal slope abnormalities do not necessarily have to be expected
in individuals with stress-related symptoms.
Moreover, no significant effects of age, sex, IQ, and psycho-
pathology symptom scores on cortisol levels were found. Interestingly,
the lower cortisol levels compared to HC remained after excluding
22q11DS participants with a psychiatric diagnosis or medication use.
This indicates that the reported lower cortisol levels found in the
22q11DS group are present irrespective of sex, age, and psychopatho-
logical factors, pointing towards alternative mechanisms that may
better explain our findings, as is discussed below.
4.2. Cortisol reactivity to activity-related stress
Lower cortisol levels in 22q11DS, combined with previous findings
indicating high levels of chronic stress in (infancy in) 22q11DS (Beaton
and Simon, 2011), suggest an abnormal biological reactivity (possibly
related to haploinsufficiency of 22q11.2 genes) to stressful situations.
Fig. 2. Cortisol reactivity to recent stressful activities, in 22q11.2 deletion
syndrome (22q11DS; n= 27) versus healthy controls (HCs; n= 24). Modelled
change (based on regression coefficient) in untransformed cortisol values
(nmol/l) following daily activity stress (within 90min). 22q11DS have a sig-
nificant different cortisol reactivity compared to HC (see Table 2 for statistics).
Activity stress was based on the average score of 2 ESM items (See Table 1).
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Interestingly, we also found a differential pattern of cortisol stress-re-
activity in the 22q11DS group compared to HCs which is in line with
our hypothesis. These findings should be interpreted with caution,
however, since the activity-related stress was trend significantly (posi-
tively) associated with cortisol in the HC group, and the negative as-
sociation in the 22q11DS group failed to reach significance.
The results indicate that 22q11DS seems to have a blunted cortisol
response to activity-related stress, consistent with some studies in
psychotic disorder (Zorn et al., 2017; Vaessen et al., 2018), individuals
at ultra-high risk for psychosis (Pruessner et al., 2013)first episode
psychosis (van Venrooij et al., 2012) and females with major depressive
and anxiety disorders19. In 22q11DS, sensitization of the HPA-axis
could lead to a dissociation between the endocrinological stress re-
sponse and the daily (minor) activity-related stress (Yehuda et al.,
1996). This notion is supported by a study showing no effect of sup-
pressing HPA-axis activity in HCs on subjective stress reports, in-
dicating that the emotional stress experienced remained intact even
when the HPA-axis response was suppressed (Ali et al., 2017).
However, we did not find any effect of psychotic symptomatology
on cortisol stress reactivity, indicating that the cortisol reactivity ab-
normalities are present in 22q11DS individuals regardless of psychiatric
symptoms. Moreover, we did not find higher childhood trauma scores,
nor an effect of childhood trauma on cortisol reactivity in 22q11DS
individuals, which was expected based on previous research suggesting
a role for childhood related stress in the etiophathology of psychiatric
symptoms in individuals with 22q11DS (Beaton and Simon, 2011).
To summarize, psychological mechanisms in individuals with
22q11DS related to stress, such as psychopathology, do not appear to be
plausible explanations for our findings. The 22q11DS has unique ge-
netic characteristics, suggesting that the observed results could be ex-
plained by the biological mechanisms associated with 22q11DS.
4.3. Biological mechanisms
There are several possible underlying biological mechanisms
causing the suggested lower cortisol levels and blunted cortisol stress
reactivity found in adults with 22q11DS. Research from twin studies
established that genetic factors account for a significant portion of the
variation in HPA-axis functioning (Tucker-Drob et al., 2017). A possible
explanation could therefore be the haploinsufficiency for genes in the
deleted region, suggested to be related to the increased risk for devel-
oping psychiatric disorders in 22q11DS individuals (Boot et al., 2011;
Gothelf et al., 2014). Hemizygosity of the proline (dehydrogenase)
oxidase 1 gene (PRODH), encoding the enzyme that catalyzes the
conversion of proline to glutamate and has effects on the NMDA re-
ceptor (Ferreira et al., 2012, no date), could potentially be related to
aberrant stress-reactivity in 22q11DS because glutamate and the NMDA
receptor are implicated to play an important role in the regulation of
the HPA axis (Mathew et al., 2001).
Another gene in the deleted region of 22q11DS, the Catechol-O-
methyltransferase (COMT) gene, encoding the enzyme that breaks
down especially frontal noradrenaline (NA) and dopamine (DA), is
additionally suggested to alter HPA-axis functioning (Oswald et al.,
2004). The COMT Met-allele results in lower COMT activity compared
to the Val-allele (Chen et al., 2004), and reduced COMT activity as a
result of hemizygosity is present in individuals with 22q11DS (Gothelf
et al., 2014). Especially low COMT activity, probably resulting in higher
levels of NA and DA, is associated with increased sensitivity to (early
life) stress and cortisol reactivity in healthy adults (Oswald et al., 2004;
Van Winkel et al., 2008; Collip et al., 2011; Lovallo et al., 2017).
Although cortisol levels are elevated in children with 22q11DS
(Jacobson et al., 2016; Sanders et al., 2017), we found lower cortisol
levels in adults with 22q11DS, indicating impairments in the develop-
mental trajectory of the endocrine systems. This is in line with recent
insights from a longitudinal study in HCs showing that “short term”
physiological symptoms in children were associated with
hypercortisolism, while chronic worry and social concerns predicted
lower cortisol levels 3 years later (Ma et al., 2018). A similar devel-
opmental trajectory, involving over-activation, over-sensitization, or
some sort of exhaustion of the endocrine or signaling systems over the
years, was previously suggested for DA in 22q11DS (Boot et al.,
2008a,b). Also, a hyperdopaminergic state is found to be present in
adolescents and adults with 22q11DS (Boot et al., 2008a,b; van Duin
et al., 2017) whereas later in life 22q11DS individuals have an in-
creased risk for developing early-onset Parkinson’s disease, associated
with striatal hypodopaminergia (Booij et al., 2010). We can only
speculate about potential endophenotypes related to this suggested
impairment in the developmental trajectory. As suggested in previous
research, lower cortisol levels might reflect a life history of coping with
social anxiety (Beaton et al., 2013). A 22q11.2 deletion could perhaps
also severely disrupt neurotransmission in the catecholaminergic and
endocrine systems over time. Impairments in the DA and cortisol sys-
tems may be important factors associated with increased risk for mental
disorders in individuals with 22q11DS.
To summarize, the abnormalities in cortisol reactivity and lower
cortisol levels found in our study could potentially be explained by
genetically determined abnormalities of the stress system and aberrant
developmental trajectories in 22q11DS. Future research is necessary to
shed light on the potential role of these mechanisms in stress reactivity
and its mediating role in the increased risk of developing psychiatric
and neurological problems.
4.4. Clinical implications
One might speculate how the lower cortisol levels and abnormal
cortisol stress reactivity relate to the multisystem clinical features in
adults with 22q11DS. Abnormal HPA-axis functioning was previously
found to be related to psychotic disorders (Collip et al., 2011a,b; Zorn
et al., 2017), major depressive disorder (Yehuda et al., 1996), PTSD
(Yehuda, 2002; Daskalakis et al., 2013), and other anxiety disorders
(Zorn et al., 2017). Hence, it is therefore likely to be related to psy-
chiatric problems in individuals with 22q11DS as well (prevalence±
60%, adults)(Bassett et al., 2011). This suggestion is in line with recent
research confirming the role of stress and coping in the pathway to
psychosis in individuals with 22q11DS (Armando et al., 2018). The
biologically inherited abnormal HPA-axis functioning could perhaps
precede psychopathology in 22q11DS, despite the fact that we did not
find this in the current study, including 22q11DS individuals with no or
minor psychiatric problems.
The lower cortisol levels in adults with 22q11DS could also be re-
lated to the high rates of immunological deficiencies, abnormal func-
tioning of the endocrine system, and metabolic disorders in the
22q11DS (Bassett et al., 2005; Shprintzen, 2008; Fung et al., 2015).
These disorders in 22q11DS include, amongst others, obesity (35%,
adults), autoimmune diseases, hypocalcemia (> 60%, attributable to
hypoparathyroidism), and related (psychosomatic) symptoms like fa-
tigue and emotional irritability (Mcdonald-Mcginn et al., 2015;
Scandurra et al., 2013; Vergaelen et al., 2017). Our results on altered
cortisol functioning add valuable new evidence for the endocrine im-
pairments in individuals with 22q11DS. More research would therefore
be necessary to further investigate the exact association between cor-
tisol levels and the clinical multisystem features in 22q11DS.
4.5. Strengths, limitations and future directions
With this study we investigated cortisol stress reactivity in a unique
sample of adult individuals with 22q11DS for the first time, using the
well-validated ESM method (Myin-Germeys et al., 2009). It is important
to note several limitations to our methods, however. First, the high
number of 22q11DS participants that had to be excluded from the final
analyses based on the generally accepted exclusion criteria (compliance
to ESM protocol of< 33% (Delespaul, 1995)) and the significantly
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lower number of assessments filled out by the 22q11DS group (Table 1)
could imply that the diary method in its current form is not appropriate
for this patient group. Although previous studies using ESM demon-
strated the feasibility and reliability of this method in vulnerable po-
pulations (Delespaul, 1995; Myin-Germeys et al., 2000; Shiffman et al.,
2008; Myin-Germeys et al., 2009), future research should consider the
vulnerability of the population and possible deviations in compliance
rate in the design of the protocol and the PsyMate™ questions.
Second, although the activity-stress item has previously been used
in comparable studies (Jacobs et al., 2007; Vaessen et al., 2018), it is
important to note that in the current study, “activity stress” was defined
using only two questions, possibly not reliably representing all cate-
gories of current daily stressors. Short-lived stressful moments, such as
daily hassles, could for instance occur in between two assessment
periods, and may not be captured by the momentary assessment pro-
tocol used. Third, several factors, such as physical activity, that can
influence cortisol levels (Miller et al., 2007; Nicolson, 2008) were not
taken into account in the current ESM protocol. Future investigation
may incorporate these measures.
Fourthly, as mentioned before, it is possible that the retrospective
and momentary questionnaires used were not capturing the current-
and childhood stressors, concealing potential associations between
cortisol and childhood trauma or psychopathology in our sample.
Future research may include more comprehensive assessment tools for
psychopathology, affect, anxiety, and (chronic childhood) stress-related
symptoms.
Finally, it should be noted that the sample of 22q11DS participants
was heterogenous in their psychopathological profile and medication
use, despite that the majority comprised of relatively high functioning
patients (in terms of daily life functioning). This could potentially ex-
plain the absence of significant associations between chronic childhood
stress, psychopathology, and cortisol. Research in a larger sample in-
cluding more patients with (mild) psychiatric symptoms with 22q11DS
will enable the possibility to create (more) homogenous clinical sub-
groups, which may provide additional insight in the association be-
tween psychopathology and cortisol stress-reactivity and possible
causal factors like childhood trauma.
5. Conclusion
The current report demonstrates, for the first time, lower overall
cortisol levels in adults with 22q11DS and attenuated cortisol response to
daily stress, independent of medication use and psychiatric diagnosis.
This could potentially be related to hemizygosity of genes located on
22q11.2 and could imply a permanent long-term effect of chronic stress.
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